Hirtle Callaghan & Co’s Teva Pharmaceuticals TEVA Stock Holding History

Hirtle Callaghan & Co’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-1,339	Closed	-$77K	–	329
2014 Q4	$77K	Hold	1,339	–	–	0.02%	257
2014 Q3	$72K	Hold	1,339	–	–	0.01%	272
2014 Q2	$70K	Hold	1,339	–	–	0.01%	323
2014 Q1	$71K	Hold	1,339	–	–	0.01%	313
2013 Q4	$54K	Hold	1,339	–	–	0.01%	325
2013 Q3	$51K	Buy	+1,339	New	+$52.2K	0.01%	340

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Hirtle Callaghan & Co's TEVA Position: Q1 2015 in Review

Hirtle Callaghan & Co sold out of Teva Pharmaceuticals (TEVA) in Q1 2015, closing a stake of 1,339 shares — an estimated $77K sold.

Hirtle Callaghan & Co first reported a position in TEVA in Q3 2013 and held it in 6 quarters. The position peaked at $77K in Q4 2014. 821 funds tracked by Wall St. Rank hold TEVA as of Q1 2015.

Hirtle Callaghan & Co reported no remaining Teva Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
Hirtle Callaghan & Co sold 1,339 Teva Pharmaceuticals shares in Q1 2015, an estimated $77K.
Hirtle Callaghan & Co first reported a position in Teva Pharmaceuticals in Q3 2013 and held it in 6 quarters.
Hirtle Callaghan & Co's Teva Pharmaceuticals position peaked at $77K in Q4 2014.
821 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2015.

Based on Hirtle Callaghan & Co's 13F filing for Q1 2015, filed 15 May 2015.